Also published on: XV SO 2021, XVI SO 2022, XVIII SO 2024
Is this your profile? Do login to access your certificatesSobre o controle utilizado
Publication: EXTRACELLULAR VESICLES RELEASED BY HUMAN ADIPOSE TISSUE FROM OBESE SUBJECTS INDUCE EPITHELIAL-MESENCHYMAL TRANSITION OF BREAST CANCEL CELLS
Gostaria de saber se sendo obtido de pacientes de cirurgias plásticas também não teriam um certo nível de sobrepeso? E neste caso apresentarem já um nível de citocinas pró-inflamatórias?
Olá parabéns pelo trabalho
Publication: VITAMIN K DERIVATIVES AS CANDIDATES OF WILD-TYPE p53 ACTIVATORS
Gostaria de saber se pretende testar esses compostos em outros tipos de tumores que também apresentem mutação em p53?
Olá parabéns pelo trabalho!
Publication: ANTITUMOR EVALUATION IN VITRO OF NAPHTHOQUINONES MANNICH BASES FOR POSSIBLE TREATMENT OF OSCC
Que tipos de testes pretende fazer para avaliação da morte celular?
A que atribui o resultado com o MB1? Estrutura?
confluência celular
Publication: METABOLIC PROFILE OF TUMOR SKIN CELLS AFTER LOW-LEVEL LASER THERAPY
Olá fiquei com dúvidas quanto a confluência celular? As células estavam confluêntes durante o ensaio? Testou diferentes níveis de confluência?
dúvida
Publication: EXTRACELLULAR VESICLES RELEASED BY HUMAN ADIPOSE TISSUE FROM OBESE SUBJECTS INDUCE EPITHELIAL-MESENCHYMAL TRANSITION OF BREAST CANCEL CELLS
Poderia explicar melhor o obese SAT and obese VAT? qual a diferença?
2 publications
2 publications
2 publications
2 publications
1 publication
1 publication
1 publication
1 publication
1 publication
1 publication
1 publication
1 publication
XVIII SO 2024
INVESTIGATING THE ROLE OF β1 INTEGRIN IN HER-2 POSITIVE BREAST CANCER
FRONTIERS 2024
Proteomic characterization following compressive sciatic nerve injury in mice treated with inosine
XVI SO 2022
THE MOLECULAR SIGNATURE OF EXOSOME-RELATED PROTEINS IS DISRUPTED BY HISTONE DEACETYLASE ACTIVITY INHIBITION IN THE GLIOBLASTOMA SECRETOME: IN SILICO AND IN VIVO CHARACTERIZATIO
XVI SO 2022
INCREASED MIGRATORY CAPACITY OF HER2+ BREAST CANCER TUMOR CELLS AFTER TREATMENT WITH TRASTUZUMAB
XVI SO 2022
EXPRESSION EVALUATION OF HER-2 AND β1 INTEGRIN IN HER-2+ BREAST CANCER CELLS LINES AFTER TREATMENT WITH TRASTUZUMAB
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper